Search results
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
Tri-County Times· 7 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
Eli Lilly Reports More than 50% Remission Rate in Crohn's Treatment Trial
Morningstar· 3 days agoEli Lilly reports that more than half of Crohn's disease patients achieved clinical remission after a year of treatment with mirikizumab in a recent trial. The pharmaceutical company said Tuesday ...
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From...
WPRI Providence· 4 days agoBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients ...
Report highlights gaps in access, stewardship plans for promising antimicrobials
Center for Infectious Disease Research and Policy· 10 hours agoA new report suggests a handful of innovative antimicrobials that could be approved within the next few years could save up to 160,000 lives if made available, and used appropriately, in the ...
Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer
Proactive Investors· 4 days agoLisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New...
Digital Journal· 4 days ago-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines